Navigation Links
Clinical Trial Participation Unaffected by Disclosure of Investigator's Financial Stake, Food and Drug Law Journal Article Finds
Date:12/18/2007

WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- The willingness to participate in a clinical investigation of a new drug or device is not affected by the investigator's financial stake in the outcome of the trial, concludes a new study reported in an article in the latest issue of the Food and Drug Law Journal, published by the Food and Drug Law Institute.

Clinical studies are essential to obtain FDA approval of new drugs and certain devices. These studies are conducted by clinical investigators, who sometimes have a financial stake in the outcome of the clinical trial, or financial ties with the sponsor of the investigation. While there has been considerable discussion regarding when these financial interests must be disclosed to potential study participants -- and more broadly, when financial interests must be publicly disclosed -- the actual impact of this disclosure on potential study subjects has received much less attention.

Now, according to a study conducted by Gregory A. Guagnano, Ph.D., Associate Professor of Sociology and Anthropology at George Mason University (GMU) (Fairfax, Virginia) and Jeffrey N. Gibbs of Hyman, Phelps & McNamara, P.C. (Washington, DC), there's evidence that the investigator's financial stake in the trial may not be that important an issue for potential participants.

Guagnano and Gibbs asked 297 undergraduate students at GMU how likely they would be to agree to participate in a study involving a dietary supplement that might improve memory. Students were either told that the investigator was an employee of the company, that he was an employee and consultant, or that he was an employee and a patent holder. The study found that the willingness to participate was not affected by these three different conflict of interest disclosures. The study did find that students who rated the investigator as more trustworthy were more likely to agree to participate, but that the evaluation of trustworthiness was not influenced by the extent of the investigator's financial stake.

On the other hand, offering the students money did significantly affect their willingness to participate. Students who were told they would receive $20 were significantly more likely to want to participate than students offered no money.

Commented Guagnano, "The study suggests that learning about an investigator's financial stake may have a relatively limited impact on deciding whether to participate. If replicated, these findings could affect the way in which clinical study disclosure requirements are established and implemented."

Gibbs added, "There are a number of reasons to mandate disclosures, but this study suggests that disclosure of conflicts may not play a large role in decision-making. Given that some courts have reached decisions based on their believing that knowledge of a financial stake would actually change people's behavior, this study shows that courts need to rely on facts, not assumptions."

The article appears in Vol. 62, Issue 4 of the Food and Drug Law Journal.

For more information or to obtain a copy of the article, contact Michael Levin-Epstein, Editor-in-Chief, FDLI, (202) 222-0897; mdl@fdli.org

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field. For more information, visit http://www.fdli.org


'/>"/>
SOURCE Food and Drug Law Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
(Date:5/4/2017)... LAWRENCE, Mass. and SAN DIEGO ... of Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and ... of single-use, self-contained, illuminating medical devices, today announced the ... size of its OfficeSPEC and ER-SPEC ... large, the addition of extra-small and extra-large sizes makes ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... , ... Dr. Alan I. Benvenisty, MD is dual board certified in general ... for his distinguished expertise and experience in the diagnosis and treatment of vascular diseases. ... renovascular disease and aortic aneurysm . He is known for his minimally invasive ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Manju ... comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal understands the ... she offers convenient, clear braces in Cincinnati, OH. Patients no longer need to feel ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. ... of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate ... in his field by attending numerous CE courses each year. His recent course, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... If you are thinking of a visit to ... in business architecture, October is the perfect time to visit. , Business Architecture Associates is ... la carte offering for individuals, as a 4-½ day package for individuals, and as 4-½ ...
(Date:5/24/2017)... ... May 24, 2017 , ... Fiberstar, ... solutions for the food and beverage industry offers Citri-Fi®, a natural citrus fiber, ... the purchasing decision process. As a result, labels need to deliver simple, transparent ...
Breaking Medicine News(10 mins):